Journal issues > Issue 6, October 2025 > Pneumonitis in a patient treated with peptide receptor radionuclide therapy for atypical lung carcinoid: nothing is what it seems

Pneumonitis in a patient treated with peptide receptor radionuclide therapy for atypical lung carcinoid: nothing is what it seems

By: E. Peys MD, K. De Muynck MD, E. De Droogh MD, D. Galdermans MD, D. Schrijvers MD, PhD, C. Deroose MD, PhD

SUMMARY

Atypical carcinoid tumours (AC) of the lung are rare neuro-endocrine neoplasms (NENs). Peptide Receptor Radionuclide Therapy (PRRT) has emerged as a pivotal treatment for advanced NENs, that can also be used for bronchial NENs. It makes use of the overexpression of somatostatin receptors (SSTR) to deliver targeted radiation. This report highlights a case of pneumonitis following PRRT in a patient with metastatic AC, underscoring its distinction from radiation pneumonitis (RP).

(BELG J MED ONCOL 2025;19(6):296–299)

To read the full artice you have the following options:

Click here to log in. Register for a free subscription*

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top